Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples

Journal of Mass Spectrometry

Volumn 42, Issue 4, 2007, Pages 440-449

  Rochat, Bertrand ^a   Bolay, Saskia ^a   Pascual, Andres ^a   Calandra, Thierry ^a   Marchetti, Oscar ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anti fungal drug; Caspofungin; Liquid chromatography; Plasma; Tandem mass spectrometry

Indexed keywords

ACETONITRILE; BLOOD; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMAS; PROTEINS;

ANTIFUNGAL DRUGS; CASPOFUNGIN; TANDEM MASS SPECTROMETRY;

ANTIBIOTICS;

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPRENAVIR; CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; IMIPENEM; INDINAVIR; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; NELFINAVIR; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TEICOPLANIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ARTICLE; CALIBRATION; DRUG ADSORPTION; DRUG ISOLATION; DRUG STRUCTURE; ELECTROSPRAY; HUMAN; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

ADULT; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; PEPTIDES, CYCLIC; TANDEM MASS SPECTROMETRY;

EID: 34247466052     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1171     Document Type: Article

References (29)

1. McCormack PLPerry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049.
2. Villanueva A, Arathoon E, Gotuzzo E, Berman R, DiNubile M, Sable C. A randomized double-blind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin. Infect. Dis. 2001; 33: 1529.
3. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 2002; 113: 294.
4. Mora-Duarte J, Betts R, Rotstein C, Lopes-Colombo A, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J, for the Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 2002; 347: 2020.
5. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 2004; 351: 1391.
6. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 2004; 39: 1563.
7. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 2002; 46: 245.
8. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 2004; 39: 797.
9. Aliff T, Maslak P, Jurcic J, Heaney M, Cathcart K, Sepkowitz KA, Weiss M. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. Cancer. 2003; 97: 1025.
10. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292.
11. Stone J, Migoya E, Li S, Deutsch P, Winchell G, Ghosh K, Miller A, Bi S, Bass A, Mistry G, Dawkins R. Safety and pharmacokinetics of higher doses of caspofungin. 42nd ICAAC. San Diego, 2002.
12. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 2002; 46: 739.
13. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 2005; 49: 4536.
14. Stone J, Holland S, Li S, Wickersham P, Deutsch P, Winchell G, Hesney M, Bi S, Friel M, Mistry G, Dilzer S, Lasseter K. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. 41st ICAAC. Chicago, 2001.
15. Stone J, Holland S, Wickersham P, Deutsch P, Winchell G, Hesney M, Miller R, Freeman A, Dilzer S, Lasseter K. Drug interactions between caspofungin and tacrolimus. 41st ICAAC. Chicago, 2001.
16. Stone JA, McCrea J, Wickersham PJ, Holland SD, Deutsch PJ, Bi S, Cicero T, Greenberg H, Waldman SA. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. 40th ICAAC, Toronto, Ontario, 2000.
17. Chavez-Eng CM, Schwartz M, Constanzer ML, Matuszewski BK. Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J. Chromatogr. B Biomed. Sci. Appl. 1999; 721: 229.
18. Egle H, Trittler R, Kummerer K. An advanced double column-switching technique (LC-LC) for liquid chromatography/electrospray ionisation tandem mass spectrometry for fully automated analysis of caspofungin. Rapid Commun. Mass Spectrom. 2004; 18: 2871.
19. Schwartz M, Kline W, Matuszewski B. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal. Chim. Acta 1997; 352: 299.
20. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem. 1998; 70: 882.
21. Naidong W, Bu H, Chen YL, Shou WZ, Jiang X, Halls TD. Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma. J. Pharm. Biomed. Anal. 2002; 28: 1115.
22. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003; 75: 3019.
23. Colombo S, Beguin A, Telenti A, Biollaz J, Buclin T, Rochat B, Decosterd LA. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 819: 259.
24. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J. Chromatogr. B 2006; 830: 293.
25. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 2000; 17: 1551.
26. FDA, U.S. Department of Health and Human Services. 2001; Guidance for industry: bioanalytical method validation, http://www.fda.gov/cder/guidance/ 4252fnl.pdf.
27. Qin XZ, Wu Y, Zhao Z, Chen X. Collision-induced dissociation of protonated MK-0991: novel ring opening of a cyclic hexapeptide in the gas phase. J. Mass Spectrom. 1999; 34: 733.
28. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 2006; 44: 760.
29. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 1998; 36: 2950.